Innogen’s Newly Approved GLP-1 Contender Girds For China Ozempic Battle

 
• By Dexter Jie Yan
  
insulin injection
Innogen's Diabegone is a newly approved homegrown contender to Novo Nordisk's Ozempic in China's domestic market. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Business